COVID-19 in PID Survey
COPID19
Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey
1 other identifier
observational
200
1 country
1
Brief Summary
With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID). Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH \& IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19". COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password. Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 15, 2020
CompletedFirst Submitted
Initial submission to the registry
July 2, 2020
CompletedFirst Posted
Study publicly available on registry
July 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 18, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 18, 2027
March 5, 2025
March 1, 2025
6.9 years
July 2, 2020
March 3, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Survival of patients with PID affected by COVID-19
Baseline
Rate of admission to ICU of patients with PID affected by COVID-19
Baseline
Rate of oxygen therapy of patients with PID affected by COVID-19
Baseline
Secondary Outcomes (1)
Sequelae of patients with PID affected by COVID-19
Baseline
Eligibility Criteria
All patients with Primary Immune Deficiency and COVID-19
You may qualify if:
- Diagnosed with a Primary Immune Deficiency
- COVID-19 (proven or probable)
You may not qualify if:
- Secondary Immune Deficiency
- Other Coronovirus infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Imagine Institute
Paris, 75015, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Nizar MAHLAOUI, MD, MPH, PhD
Necker Enfants Malades University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 2, 2020
First Posted
July 7, 2020
Study Start
March 15, 2020
Primary Completion (Estimated)
February 18, 2027
Study Completion (Estimated)
February 18, 2027
Last Updated
March 5, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share